This content is from: Premium

This Surging Biotech Company Has Attracted a Web of Hedge Fund Managers

Several big-name hedge funds are enjoying gains from Axovant Sciences, whose parent company was founded by a former hedge fund manager.

A small clinical-stage biotech company that more than doubled in price on Wednesday had previously attracted a large group of high-profile hedge fund managers.Shares of Axovant Sciences surged 160 percent, to close at $4.55, on Wednesday after the company announced it licensed the exclusive worldwide rights to develop and commercialize

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content